The correction is positive for existing shareholders — the option exchange overhang is 76% smaller than originally feared. However, the proposal still transfers value from shareholders to option holders by repricing underwater options. Monitor the June 16 vote outcome; if approved, the exchange will occur immediately. The stock's $4.09 close suggests the market has already priced in significant dilution risk — this correction may provide a modest relief rally.
Price Chart
Executive Summary
Agenus filed a DEFA14A supplement correcting a material error in its April 30 proxy statement: the number of options eligible for the proposed one-time exchange was overstated by 4x (8,697,165 originally stated, corrected to 2,103,891). The exchange would replace deeply underwater options (weighted-average exercise price $46.27 vs. $4.09 closing price) with new options at fair market value for most employees and at a 150% premium for executives/directors. The correction reduces the perceived dilution and overhang from the proposal, but the underlying retention rationale and vote mechanics are unchanged.
Key Facts
- Corrected eligible option count from 8,697,165 to 2,103,891 — a 76% reduction
- Eligible options have weighted-average exercise price of $46.27 vs. $4.09 closing price (100% underwater)
- CEO Garo Armen holds 838,377 of 2,103,891 total eligible options (39.9%)
- Proposal 4 is a one-for-one option exchange with 150% premium strike for Tier 1 (executives/directors) and 100% FMV for Tier 2
- Special meeting scheduled for June 16, 2026; majority of votes cast required for approval
- Broker non-votes and abstentions have no effect on Proposal 4 outcome
Financial Impact
No direct dollar impact. The correction reduces potential accounting compensation cost from the exchange by ~76% vs. the erroneously stated figure. Incremental compensation cost measured as excess of new option fair value over surrendered option fair value.
Risk Factors
- Option exchange still dilutes existing shareholders if stock appreciates above new strike prices
- CEO holds ~40% of eligible options — concentrated insider benefit from repricing
- No guarantee of FDA accelerated approval for BOT+BAL in 2026 — binary regulatory risk remains
- Company reduced net burn from >$200M to ~$50M but still cash-flow negative
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001193125-26-221408 |
| Document: 0001193125-26-221408-index-headers.html | 0001193125-26-221408 |
| Document: 0001193125-26-221408-index.html | 0001193125-26-221408 |
| Document: 0001193125-26-221408.txt | 0001193125-26-221408 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 13, 2026 7w ago | 8-K | $7.00 $6.94 | ▼ −0.86% | ▲ +0.89% | $8.36 (+19.43%) |
Aug 12, 2026 7w ago | Institutional Cluster | $6.90 $6.89 | ▼ −0.14% | ▲ +1.75% | $8.36 (+21.16%) |
Aug 7, 2026 8w ago | S-3 | $7.00 $7.76 | ▼ −10.87% | ▼ −11.78% | $8.36 (−19.43%) |
Aug 6, 2026 8w ago | 8-K | $7.49 $8.24 | ▲ +10.01% | ▲ +9.41% | $8.36 (+11.62%) |
Jul 18, 2026 10w ago | S-3 | $4.97 $7.15 | ▼ −43.86% | ▼ −39.74% | $8.36 (−68.21%) |
Jul 13, 2026 11w ago | 8-K | $6.12 $7.00 | ▼ −14.38% | ▼ −11.19% | $8.36 (−36.60%) |
May 13, 2026 20w ago | DEFA14A | $3.47 $3.39 | ▼ −2.31% | ▼ −1.69% | $8.36 (+140.92%) |
May 11, 2026 20w ago | 8-K | $3.26 $3.11 | ▼ −4.60% | ▼ −4.30% | $8.36 (+156.44%) |
Dec 4, 2025 43w ago | Court Ruling | $4.06 $3.22 | ▲ +20.69% | ▲ +21.18% | $8.36 (−105.91%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access